|
Miltenyi Biotec
anti c myc fitc Anti C Myc Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti c myc fitc/product/Miltenyi Biotec Average 96 stars, based on 1 article reviews
anti c myc fitc - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
R&D Systems
anti myc ![]() Anti Myc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti myc/product/R&D Systems Average 94 stars, based on 1 article reviews
anti myc - by Bioz Stars,
2026-03
94/100 stars
|
Buy from Supplier |
|
Bio-Rad
mouse anti cmyc ![]() Mouse Anti Cmyc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mouse anti cmyc/product/Bio-Rad Average 93 stars, based on 1 article reviews
mouse anti cmyc - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti myc antibodies ![]() Anti Myc Antibodies, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti myc antibodies/product/Miltenyi Biotec Average 96 stars, based on 1 article reviews
anti myc antibodies - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
hrp labelled anti myc antibody ![]() Hrp Labelled Anti Myc Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/hrp labelled anti myc antibody/product/Miltenyi Biotec Average 96 stars, based on 1 article reviews
hrp labelled anti myc antibody - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
c myc antibody ![]() C Myc Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/c myc antibody/product/Miltenyi Biotec Average 92 stars, based on 1 article reviews
c myc antibody - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Cusabio
mouse anti myc ![]() Mouse Anti Myc, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mouse anti myc/product/Cusabio Average 90 stars, based on 1 article reviews
mouse anti myc - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Sino Biological
anti myc mouse monoclonal antibody ![]() Anti Myc Mouse Monoclonal Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti myc mouse monoclonal antibody/product/Sino Biological Average 93 stars, based on 1 article reviews
anti myc mouse monoclonal antibody - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Sino Biological
myc ![]() Myc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/myc/product/Sino Biological Average 94 stars, based on 1 article reviews
myc - by Bioz Stars,
2026-03
94/100 stars
|
Buy from Supplier |
|
R&D Systems
c myc ![]() C Myc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/c myc/product/R&D Systems Average 93 stars, based on 1 article reviews
c myc - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
OriGene
ta150044 ![]() Ta150044, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/ta150044/product/OriGene Average 92 stars, based on 1 article reviews
ta150044 - by Bioz Stars,
2026-03
92/100 stars
|
Buy from Supplier |
|
Genecopoeia
mouse monoclonal anti gst ![]() Mouse Monoclonal Anti Gst, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/mouse monoclonal anti gst/product/Genecopoeia Average 95 stars, based on 1 article reviews
mouse monoclonal anti gst - by Bioz Stars,
2026-03
95/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a Approaches for RNA-seq of HCC cells in the indicated groups. b The top Hallmark gene sets enriched in HCC cells from Cre Alb Myc mice compared to Cre Alb Scarb2 F/F Myc mice. P value was determined by one-sided permutation test. Statistical adjustments were made for multiple comparisons. c , d GSEA showing the enrichment of MYC target genes in Cre Alb Scarb2 F/F Myc vs Cre Alb Myc groups. P value was determined by one-sided permutation test. Statistical adjustments were made for multiple comparisons. e Visualization of SCARB2 positive and negative cells in tumorspheres by UMAP. f The proportion of SCARB2 positive cells in tumorspheres was analyzed by scRNA-seq. g , h Visualization of SCARB2 and MYC target genes expression in tumorspheres by UMAP. i Violin plot showing expression levels of MYC target gene score in SCARB2 positive and negative cells. The tips of the violin plot represent minima and maxima, and the width of violin plot shows the frequency distribution of data. j Correlation expression of MYC target genes and SCARB2 expression in SCARB2 positive cells. Each data point represents the value from an individual cell. k Effects of SCARB2 deletion or overexpression on the transcriptional activity of MYC. l Heatmap showing occupancy of genome-wide MYC peaks in CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells in a ± 3 kb window surrounding the TSS. m Metagene plots of global MYC occupancy in gene bodies in CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells. n CUT & tag tracks showing the binding of MYC to CDK4 and SLC2A1 in CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells. o , p CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells ( o ) or HCC cells from Cre Alb Myc and Cre Alb Scarb2 F/F Myc mice ( p ) were analyzed by ChIP with MYC or IgG antibody. ChIP’d DNA was quantified using qPCR for MYC or IgG binding to MYC target genes promoters. q Effect of SCARB2 knockout on the interaction MYC with MAX. Extracts of CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells were IP anti-MYC Ab and blotted with an anti-MAX Ab. r Colocalization of MYC and MAX in CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells was detected by the Duolink PLA assay. Data are representative images of MYC/MAX foci (left) and quantification of the number of fluorescent foci ( n = 8 cells per group). Scale bar, 5 μm. k , o , p , q , r n = 3 biological repeats. Statistical significance was calculated by ( i , k , o , p , r ) two tailed Student’s t test; ( j ) two-sided Pearson’s correlation test; Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: RNA Sequencing Assay, Expressing, Over Expression, Activity Assay, Genome Wide, Binding Assay, Knock-Out, Two Tailed Test
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a The effects of SCARB2 deletion on the acetylation of MYC were assessed by Co-IP. b The effects of SCARB2 overexpression on the acetylation of MYC were assessed by Co-IP. c Effects of SCARB2 on the acetylation of MYC K148R mutants. HEK 293 T cells were transfected with the indicated plasmids for 24 h. Cell extracts were IP with an anti-MYC Ab. Acetylated MYC was detected by immunoblotting. d Effect of SCARB2 overexpression on HDAC3-mediated deacetylation. HCCLM3 cells were transfected with the indicated plasmids for 24 h. Cell extracts were IP with an anti-MYC Ab. Acetylated MYC was detected by immunoblotting. e Sequencing verification of the codon replacement by CRISPR-Cas9 resulting in MYC K148R . f Effect of HDAC3 overexpression on acetylation of MYC in MYC WT and MYC K148R HCCLM3 cells. g Effects of the MYC K148R mutation on MYC transcriptional activity in HCCLM3 cells with or without SCARB2 depletion. Data are means ± S.E.M of 3 independent experiments. h MYC WT and MYC K148R HCCLM3 cells were analyzed by ChIP with MYC or IgG antibody. ChIP’d DNA was quantified using qPCR for MYC or IgG binding to MYC target genes promoters, CAD , CDK4 , LDHA , NCL , PKM2 , HES1 , or Chr6 (negative control). i Effects of the K148R mutation on the interaction of MYC with BRD4, KAT5, and GCN5. j Effect of the MYC K148R mutation on the proliferation of HCCLM3 cells with or without SCARB2 depletion . k Effects of the MYC K148R mutation on the sphere-forming ability of HCCLM3 cells with or without SCARB2 depletion. l Schematic showing the role of MYC K148 acetylation in providing a potential docking site for binding with GCN5, KAT5, and BRD4. a , b , c , d , f , g , h , i , j , k n = 3 biological repeats. Statistical significance was calculated by ( g , h , j , k ) two tailed Student’s t test. Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: Co-Immunoprecipitation Assay, Over Expression, Transfection, Western Blot, Sequencing, CRISPR, Mutagenesis, Activity Assay, Binding Assay, Negative Control, Two Tailed Test
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a MS analyzed the interaction proteins of SCARB2 in HCCLM3 cells. b The interaction between MYC and SCARB2 in HCCLM3 cells was evaluated by Co-IP assays. c CO-IP analysis of SCARB2 and MYC interaction in the cytoplasm, cytomembrance and nucleus of HCCLM3 cells. d Co-localization of MYC/SCARB2 was detected in HepG2 cells with immunostaining. Scale bar, 5 μm. e The interaction between MYC and HDAC3 in CTRL Cas9 and SCARB2 Cas9 HCCLM3 cells was evaluated by Co-IP assays. f Co-localization of MYC and HDAC3 was detected in CTRL Cas9 and SCARB2 Cas9 HepG2 cells by immunostaining. Scale bar, 20 μm. g Mapping of MYC regions binding to SCARB2 and HDAC3. Left: deletion mutants of MYC. Right: HEK 293 T cells were cotransfected with the indicated constructs of MYC (GFP tag) and SCARB2 (Myc tag) or HDAC3 (HA tag). Cell extracts were IP with an anti-Myc Ab or anti-HA Ab. h Mapping of SCARB2 regions binding to MYC. HEK 293 T cells were cotransfected with the indicated constructs of SCARB2 (Myc-tagged) and MYC (Flag-tagged). Cell extracts were IP with an anti-Flag. i HCCLM3 cells treated with or without HDAC3 inhibitor (RGFP966 5μM) were analyzed by ChIP with MYC or IgG antibody. ChIP’d DNA was quantified using qPCR for MYC or IgG binding to MYC target genes promoters, CAD , CDK4 , LDHA , NCL , PKM2 , HES1 , or Chr6 (negative control). j Relative cell viabilities of HCCLM3 SCARB2 cas9 cells or HepG2 SCARB2 cas9 cells with overexpression of the indicated genes for the indicated times. k Sphere-forming capacity of HCCLM3 SCARB2 cas9 cells with overexpression of HDAC3 or HDAC3 R265P mutation. b , c , d , e , f , g , h , i , j , k n = 3 biological repeats. Statistical significance was calculated by ( i , j , k ) two tailed Student’s t test. Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: Co-Immunoprecipitation Assay, Immunostaining, Binding Assay, Construct, Negative Control, Over Expression, Mutagenesis, Two Tailed Test
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a – b Virtual screening of FDA-approved drugs to identify small molecules binding with SCARB2 ( a ), top 10 hits are listed ( b ). c The kinetics of the SCARB2-PMB interaction were determined by surface plasmon resonance (SPR) analysis. d The highest scoring docking model of the SCARB2 and PMB complex is shown. Top: surface of the PMB-SCARB2 complex. Bottom: 3D structure of the PMB (yellow)-SCARB2 complex. e The kinetics of the SCARB2-MYC interaction with or without PMB were determined by SPR. f Structured illumination microscopic (SIM) images of vehicle- or PMB- treated HCCLM3 cells (1 h) stained for MYC and SCARB2. Scale bar, 10 μm. g The effect of PMB on the interaction of MYC and SCARB2 was evaluated by Co-IP assays. Extracts of DMSO and PMB-treated HCCLM3 cells were IP with an anti-SCARB2 Ab. h Representative images of MYC/HDAC3 colocalization foci in HCCLM3 cells before and after PMB treatment. Scale bar, 10 μm. i Effect of PMB on MYC acetylation. Extracts of DMSO and PMB-treated HCCLM3 cells were IP with an anti-MYC Ab. Acetylated MYC was detected by immunoblotting. j HCCLM3 cells treated with or without PMB were analyzed by ChIP with MYC or IgG antibody. ChIP’d DNA was quantified using qPCR for MYC or IgG binding to MYC target genes promoters. k Representative images and quantification of tumorspheres formed by HCCLM3 cells with indicated treatment. l Representative images and quantification of the viability of human-derived HCC organoids in 3D culture following the indicated treatment (10 organoids per group). m The frequency of tumor-initiating cells of HCC cells with or without PMB treatment were detected by in vitro limiting-dilution assays ( n = 10 per group). n – o Effects of the MYC K148R mutation on the sphere-forming ability ( n ) and proliferation ( o ) of HCCLM3 cells with or without PMB treatment. p – q Relative cell viabilities ( p ) and tumorsphere formation ( q ) of MYC- or SCARB2 -depleted HCCLM3 cells with or without PMB treatment. f , g , h , i , j , k , n , o , p , q n = 3 biological repeats. Statistical significance was calculated by ( j , k , l , n , o , q ) two tailed Student’s t test; ( m ) one-sided extreme limiting dilution analysis. Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: Binding Assay, SPR Assay, Staining, Co-Immunoprecipitation Assay, Western Blot, Derivative Assay, In Vitro, Mutagenesis, Two Tailed Test
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a Scheme used to establish the model of spontaneous HCC with targeted Myc knock-in and Scarb2 knockout in the liver. b Representative photographs (top) and H&E staining (bottom) of intrahepatic tumor tissues in the indicated mice 8 weeks after birth. Scale bar, 1 cm. H&E staining Scale bar, 100 μm. c The liver weights of WT ( n = 12 mice), Cre Alb My c ( n = 12 mice), Cre Alb Scarb2 F/+ My c ( n = 12 mice) or Cre Alb Scarb2 F/F My c mice ( n = 6 mice). d Incidence of HCC in Cre Alb My c ( n = 11 mice), Cre Alb Scarb2 F/+ My c ( n = 12 mice) or Cre Alb Scarb2 F/F My c mice ( n = 10 mice). e Kaplan–Meier survival curves for Cre Alb My c ( n = 11 mice), Cre Alb Scarb2 F/+ My c ( n = 12 mice) or Cre Alb Scarb2 F/F My c mice ( n = 10 mice). f The tumor initiation efficiency of HCC cells harvested from indicated group was evaluated by in vivo limiting dilution assay ( n = 10 mice per group). g Flow cytometric analysis of the proportion of EpCAM, CD133 or CD24 positive cells in indicated group ( n = 3 mice per group). h Scheme used to establish DEN-induced HCC mouse model. i Representative photographs (top) and H&E staining (bottom) of intrahepatic tumor tissue in the indicated mice 8 months after birth. j Liver weights of the Cre Alb mice ( n = 8 mice) and Cre Alb Scarb2 F/F mice ( n = 8 mice) in DEN-induced HCC mouse model. k Numbers of tumor nodules in the indicated mice ( n = 8 mice per group). l Effect of SCARB2 knockout in HCCLM3 cells on tumor growth ( n = 8 mice per group). Representative images of tumors ( m ) and tumor weights ( n ) in the indicated group ( n = 8 mice per group). o–q Effects of SCARB2 knockout in HCCLM3 spheroids on tumor growth, tumor sizes and tumor weights ( n = 8 mice per group). r Flow cytometric analysis of the proportion of CD24, EpCAM, CD13, or CD133 positive cells in tumors generated from HCCLM3 spheroids with or without SCARB2 knockout ( n = 8 mice per group). Statistical significance was calculated by ( c , g , j , k , l , n , o , q , r ) two tailed Student’s t test; ( d, e ) two-sided log-rank test; ( f ) one-sided extreme limiting dilution analysis. Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: Knock-In, Knock-Out, Staining, In Vivo, Limiting Dilution Assay, Generated, Two Tailed Test
Journal: Nature Communications
Article Title: SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity
doi: 10.1038/s41467-023-41593-z
Figure Lengend Snippet: a Representative images of tumors and effects of the indicated treatments on tumor growth in the HepG2, HCCLM3 and Hepa1-6 CDX mouse models ( n = 8 mice per group). b Effects of the indicated treatments on tumor weights in the indicated CDX models ( n = 8 mice per group). c The tumor formation efficiency of HCC cells harvested from HepG2 and HCCLM3 CDX-derived HCC tumors was evaluated by in vivo limiting dilution assay. ( n = 8 mice per group). d Strategy for establishing PDX models from HCC patients. e The expression of MYC and SCARB2 were examined by WB in adjacent and HCC tissues from HCC patient of PDX model. Data are representative images from three independent experiments. f Representative images of tumors in the indicated PDX models ( n = 8 mice per group). g Effects of the indicated treatments on tumor growth in the indicated PDX model ( n = 8 mice per group). h Effects of the indicated treatments on the tumor weights in the indicated PDX models ( n = 8 mice per group). i Flow cytometry analysis for ALDH activity using the ALDEFLUOR kit in PDX model with indicated treatments. j Schematic diagram illustrates that SCARB2 drives hepatic carcinoma initiation by supporting cancer stem cell traits and enhancing MYC transcriptional activity. e , i n = 3 biological repeats. Statistical significance was calculated by ( a , b , g , h , i ) two tailed Student’s t test; ( c ) one-sided extreme limiting dilution analysis. Data are presented as means ± S.E.M. Source data are provided as a Source Data file.
Article Snippet: For immunofluorescence and immunohistochemistry, the following antibodies were used:
Techniques: Derivative Assay, In Vivo, Limiting Dilution Assay, Expressing, Flow Cytometry, Activity Assay, Two Tailed Test
Journal: Developmental Cell
Article Title: Chk1 Inhibition of the Replication Factor Drf1 Guarantees Cell-Cycle Elongation at the Xenopus laevis Mid-blastula Transition
doi: 10.1016/j.devcel.2017.06.010
Figure Lengend Snippet:
Article Snippet: Mouse monoclonal anti-Myc antibody (9E10) coated magnetic beads ,
Techniques: Concentration Assay, Magnetic Beads, Recombinant, FLAG-tag, Software